REVENUE RECOGNITION (Tables)

12 Months Ended

Dec. 31, 2023

Revenue from Contract with Customer [Abstract]

Schedule of net revenue from collaborative arrangements

Net revenue recognized under our GSK Agreements was as follows:

	Year Ended December 31,
(In thousands)	2023			2022			2021
Royalties – RELVAR/BREO	$	208,042		$	215,034		$	234,066
Royalties – ANORO		44,627			38,405			44,935
Royalties – TRELEGY(1)		—			72,029			126,688
Total royalties		252,669			325,468			405,689
Less: amortization of capitalized    fees paid		(13,823	)		(13,823	)		(13,823	)
Total royalty revenue	$	238,846		$	311,645		$	391,866

(1) The year ended December 31, 2022 represents the period from January 1, 2022 to July 20, 2022, the date of the sale of our ownership interest in TRC.